Enabling technologies for efficient downstream processing ......biosimilars (market of $1.26bn in...
Transcript of Enabling technologies for efficient downstream processing ......biosimilars (market of $1.26bn in...
The world leader in serving science
Shelly A. Parra Sr. Manager, Global Field Applications
Enabling technologies for efficient downstream processing of biosimilars, vaccines and gene therapy vectors
2
• Case Studies • Biosimilars & Recombinant Proteins • Virus Like Particles • Gene Therapy
• New products on the horizon
• Closing
Overview
3
Monoclonal antibodies
• mAb-based therapeutics continue to dominate even with new cell lines emerging
• More Mab Fragments, Fabs, ADCs • Dramatic increases in cell expression levels • Interest in continuous processing
Vaccines • Processes redesigned to be more responsive, more reproducible, with higher yields
Plasma • Interest in modernizing legacy processes
Biosimilars • More drugs coming off patent, need for shorter time to end-user
Gene Therapy • Growing interest in the area and the market expected to grow 15% CAGR
First in human • Speed to clinic is main product development driver
Ease of use • Major shift to disposables in downstream purification
Quality and efficiency
• Continued demand for highest quality resolution, capacity, salt tolerance and operation speed
• Consistent, reproducible material from batch to batch • Supply risk mitigation, cost minimization
Industry Trends Driving Growth in Downstream Purification
4
BioProduction Solutions for Downstream Processing
POROS™ Ion Exchange • High performance cation and anion exchange
resins • Differentiated surface chemistries provide
unique selectivity
CaptureSelect™ Products and Services • Unique, tunable affinity ligands / resins • High purity in a single step
POROS™ Resins •High performance Ion Exchange resins
Simplifying biomolecule purification and reducing COGs
Cell Culture Clarification
Capture/Affinity Chromatography
Viral Inactivation
Polish/Non-Affinity Chromatography
Viral Filtration
Formulation
5
Protein purification challenges
• Conventional purification processes require multiple chromatographic steps (IEX, HIC, size exclusion) to effectively separate the target protein from the feedstock contaminants
6
Protein purification challenges
• Conventional purification processes require multiple chromatographic steps (IEX, HIC, size exclusion) to effectively separate the target protein from the feedstock contaminants
50% product loss
• Limit the number of steps in a purification procedure
7
Purification Can Be More Efficient
Non-Affinity Capture
Polish 1
Polish 2
Polish 3
Polish 4
Polish 5
Affinity Capture
Polish 1
Polish 2
80% reduction in purification time
Cell culturefeed
Purifiedproduct
CaptureSelect™ solution • Enabling a platform approach
for biomolecules through selectivity /specificity • High purity in single step
• Reduction of process steps • Higher yields, reduced costs
• Mild elution conditions • To retain biological activity of
target
• Efficient clearance of HCP, DNA, virus • High selectivity in capture step
Simplify recombinant protein
purification
8
Broad range of target molecules covered (RUO and cGMP)
• Antibodies • Human IgG, IgA, IgM • Multi-species IgG • Human specific • Mouse and Rat specific • Fab fragment
− CH1 − LC-kappa/lambda
• Fc fragments and Fc-fusions
• Non-Antibody targets (recombinant and plasma derived) • Blood factors: FI, FII, FVII, FVIII, FIX, vWF, • Proteins: HSA, AAT, tPA, ATIII, TF, Fib, ApoA1, ApoH • Hormones; G-CSF, FSH, hGH, hCG, GM-CSF, Insulin • Viruses: AAV serotypes, Adenovirus, Influenza • Affinity Tags: C-Tag (EPEA)
CH3
CH1
CH2
VH
CL
VL
CH3
CH1
CH2
VH
CL
VL
CH4
CH1
CH2
VH
CL
VL
CH3
CH3
CH1
CH2
VH
CL
VL
www.thermofisher.com..captureselect-affinity-products.html
9
• Case Studies • Biosimilars & Recombinant Proteins • Virus Like Particles • Gene Therapy
• New products on the horizon
• Closing
Overview
10
CaptureSelect™ bioprocess cGMP resins: proteins and viruses
Product Target applications Uniqueness
CaptureSelect™ FSH
Human follicle stimulating hormone Binds only intact FSH due to alpha/beta chain epitope
CaptureSelect™ HSA Human serum albumin, albumin fusion proteins
Mild elution conditions
CaptureSelect hCG rec Human chorionic gonadotropin Binding rec hCG with cross binding to LH and FSH
POROS® CaptureSelect™ AAV9 Adeno-associated virus type 9 (AAV9) Highly selective for AAV9 with high capacity (1e14 VG/ml)
POROS® CaptureSelect™ AAV8 Adeno-associated virus type 8 (AAV8) Selective for AAV8
Caution: For manufacturing, processing, or repacking.
FSH HSA AAV
11
CaptureSelect™ FSH Affinity Matrix Mild eluting affinity resin for intact follicle stimulating hormone
Binding specificity
Human intact FSH
Matrix and particle size
Aldehyde-activated agarose, 65 μm
Dynamic binding capacity
~3 to 5 g/L of matrix (depends on flow rate, column height, and contact time)
Elution buffer • 20 mM Tris, 2.0 M MgCl2 pH 7.0
• Mild elution, retaining
biological activity • Binding intact FSH
(conformational epitope) • Excellent scalability • Non-animal-derived
Caution: For manufacturing, processing, or repacking.
Load
2x Elutie frac003:10_UV2_280nm 2x Elutie frac003:10_Cond% 2x Elutie frac003:10_pH 2x Elutie frac003:10_Fractions
-50
0
50
100
150
200
250
mAU
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 ml2B3 2B5 2B7 2B9 2B11 2C1 2C3 2C5 2C7 2C9 2C11 2D1 2D3 2D5 2D7 2D9 2D11 2E1 2E3 2E5 2E7 Waste 2E9 2E11 2F1 2F3 2F5 2F72F9 Waste
Elution MgCl2
Strip pH 2.0
Chromatogram of the purification of FSH from clarified cell culture harvest using CaptureSelect FSH.
Red line: OD 280 nm, blue line: conductivity, grey line: pH
0.0
0.3
0.5
0.8
1.0
1.3
1.5
1.8
2.0
FSH intact alpha-chain beta-chain
Ligand 1Ligand 2Ligand 3Ligand 4anti intact FSHanti beta FSHanti hCG (alpha)
12
Case Study
Providing solutions for biosimilar development
• Follicle Stimulating Hormone (FSH) is one of the top non-mAb biosimilars (market of $1.26bn in 2013 expected to grow to ~$2bn in 2024*)
• Original process contains multiple steps, up to 7 purification steps have been reported, and has a low overall process yield
• Need for shorter and more cost effective manufacturing process
• Development program to develop an affinity resin specifically binding to FSH
• Ligand would ideally bind only the intact form of FSH
• Mild elution to contain the activity of FSH
• Collaborated with a well known biosimilar manufacturer in Egypt
• Affinity resin suitable for commercial manufacturing developed
• Binds a conformational epitope only present on intact FSH
• Increase in yield (over 3-fold has been reported)
• Decrease in number of process steps and overall COGs
SITUATION OUR RESPONSE VALUE DELIVERED
13
HSA - high capacity, mild eluting resin for HSA fusion proteins
Binding specificity
Human albumin from recombinant sources, plasma, and serum
Matrix and particle size
Aldehyde-activated agarose, 65 μm
Dynamic binding capacity
~12 g Albumin/L of matrix (5% breakthrough at 150 cm/h)
Elution buffer • Neutral: 20 mM Tris, pH 7.4, plus one of the following – 2.0 M MgCl2 – 1 M NaCl, 50%(v/v) propylene glycol, pH 7.4 – 1 M NaCl, 0.5 M L-Arginine, pH 7.4 • Acidic: Glycine, pH 3.0
• Highly selective for human
albumin • Unique elution characteristics
allowing for gentle elution of albumin fusion proteins
• Excellent scalability • Non-animal-derived
Equilibration/wash buffer: PBS, pH 7.4 Load: Feedstock of recombinant albumin fusion production Elution buffer: 20 mM Tris, 2.0 M MgCl2, pH 7.4 Flow: 200 cm/h
0
2
4
6
8
10
12
14
16
0 50 100 150 200 250 300
DBC
at C
5 (g
/L m
atrix
)
Flow (cm/h)
The dynamic binding capacity of the CaptureSelectTM albumin affinity matrix at 5% breakthrough (C5) as a function of the linear flow rate on a 5x20 mm column.
Lower flow rates during sample loading drive the dynamic binding capacity
• CaptureSelect Human Albumin
14
Pipeline of affinity products
CaptureSelect™ affinity products for purification of: Therapeutic proteins (non-mAb) & viruses Antibody types
Bioprocess cGMP
FSH, Human Albumin, hCG AAV8, AAV9,
KappaXL FcXL
IgG-CH1
Stage 5: RUO products
hGH, tPA Antithrombin III, Fibrinogen,
Transferrin, ApoH, C1-Inh
IgA, IgM CH1-XL
Stage 4: Lead Selection
Prothrombin, GM-CSF Exotoxin A (PE),
IgG-CH2
Stage 3: Prototype Resins
Insulin, EPO Adenovirus (Adv5), Flu (HA)
IgE, Free LC-kappa
Stage 2: Lead Screening
TSH, IFNa/b, hIL2, Protein C, FV, FX, FXI, FXII, FXIII, FH, vWF,
Lentivirus (VSV-G)
Rabbit IgG, Anti-Idiotypes
Stage 1: Library Construction DNAse Free LC-lambda,
scFv, IgY, Mouse IgG
15
Purification of Large Biomolecules: Viruses, VLP, Vectors, Plasmid DNA, IgM, Fusion Proteins
• Why is POROS well suited for these applications? • Unique pore morphology which increases surface area
rendering large biomolecules accessible to charged functional groups
• Ultimately increasing capacity for large biomolecules • Ability to flow at high flow rates makes the process more
flexible, scalable and productive while maintaining resolution • Easy to use and pack • Reproducible
16
POROS™ Chromatography Resin
• Backbone : Polymerized polystyrene - divinylbenzene • Unique base beads are used for different chemistries
Base Bead Average Pore Size*
(Angstroms)
Average Particle Size
(µm) Functional Chemistries
R150 2000 50 HQ, PI, IgM R250 1100 50 HS, D, HE, AAV8/9
R450 1000 45 MabCapture A/
MabCapture A Select R550 1100 50 XS, XQ
* Average pore size determined by water pore asymmetry on the base bead prior to coating and functionalization.
• Smallpox 200-400nm in diameter • Adenovirus 70-90nm in diameter • Adeno-associated virus 20nm in diameter • Papilloma virus 40-55nm in diameter
17
POROS Applications: Purification of Viruses, Virus-Like Particles (VLPs), Vectors, and Plasmid DNA
• Known applications for large biomolecule purifications center around 6 POROS Chemistries: HS50, HQ50, D50, PI50, XQ, Heparin
• Particles bind tightly as elution is typically at 0.4->1.0M NaCl • Can be employed as capture or polish chromatography step • High purity achieved in one chromatographic step • Applications in Foot & Mouth Disease, Rabies, Polio, Flu, etc
18
Case Study: POROS HS in HPV VLP Process
• Cook, James C. et al, “Purification of Virus-Like Particles of Recombinant Human Papillomavirus Type 11 Major Capsid Protein L1 from Saccharomyces cerevisiae”, Protein Expression and Purification, 1999, V 17, Pages 477-484
19
Case Study: Purification of HPV VLPs
• Single Step Chromatographic Purification
Reprinted from Cook, J., Protein Expression and Purification, 1999, V17, 477-484
20
• Advantages of POROS HS50 • Pore Structure
• “The large throughpores of POROS 50HS resin were probably accessible to the VLP,…”
• “Small pores would physically exclude the VLP and restrict binding to the outer surface of the beads, thus leading to low binding capacity.”
• Selectivity and Recovery • “Excellent selectivity of the
chromatography made it possible to achieve 98% purity” with a 2 step purification process: microfiltration and CEX Chromatography
• POROS HS50 was “the best for selectivity and recovery for this particular application”
Case Study: Purification of HPV VLPs
Reprinted from Cook, J., Protein Expression and Purification, 1999, V17, 477-484
21
Enabling Technology – POROS CaptureSelect AAV Resins
Gene Therapy
• Growing interest – lack of industrialized purification platform to meet market needs
22
• Increased interest and focus in gene therapy applications over the past decade
• Gene therapies promise versatile treatment of long-term and potentially curative benefits to patients with genetic or acquired diseases
• Of recent, > $1.2B has been secured for gene therapy companies via IPOs and VC financings
Gene Therapy – A Field that is Evolving
23
Clinical Trial Information
• United states, has the highest number of approved clinical trials (63%) taking place, however no approved product in the market
• Most of the clinical trials are in early phase development
• Successes in the space of rare genetic diseases
• The patient population afflicted by these diseases are small
• Clinical success in Phase I/II may be enough to proceed towards commercialization
Country No. of Trials
Approved Products
USA 1312 0
UK 206 1
Germany 83 0
France 51 0
China 37 2
Key Players in the Field
Interest from Pharma Companies
CMOs
24
• The Ideal Vector for Gene therapies: Cost effective to manufacture with a simple vector design
Highly precise and specific target cell delivery
Cause no damage to target cell
Effectively carry the desired genetic load
Have low immunogenicity
Capability for longer lasting expression if indications require this criteria
• Adenoassociated virus (AAV) have emerged as the vector of choice for many therapies
• AAV can effectively target most cell types
• Mediate long-term tissue-specific gene expression with low immunogenicity
Adeno-associated Virus (AAV) for Gene Therapy
25
AAV and Chromatography Solutions for Purification
26
Serotype Heparin Anion Cation AVB AAV8 AAV9
AAV1 No Yes Yes Yes No No
AAV2 Yes Yes Yes Yes No No
AAV3 Yes Yes Yes Yes No No
AAV4 No Yes Yes No No No
AAV5 No Yes Yes Yes No No
AAV6 Yes Yes Yes No No No
AAV7 No Yes Yes No No No
AAV8 No Yes Yes No Yes No
AAV9 No Yes Yes No No Yes
AAV and Chromatography Solutions for Purification
27
Harvest Centrifugation Concentration Filtration Size exclusion
Ultra Centrifugation
Ion Exchange
Diafiltration
Current Gene Therapy Purification Strategies
• Current Paradigm • Multiple chromatography
steps & concentration • Long process
development lead-times • More expensive process • Cumulative yield losses
20% product
yield
28
Enabling a Paradigm Shift in Viral Vector Purification
Harvest Centrifugation Concentration Filtration Size exclusion
Ultra Centrifugation
Ion Exchange
Dia-Filtration
Clarification Affinity Concentration Filtration
• CaptureSelect™ Paradigm • Affinity capture and
concentration only • Process simplified • Lower cost & complexity • Speed to market • Less steps = higher yield
Customer testimonial: “Process yield improvement from 20% to 60% & cost reduction by a factor of 6”
29
Enabling Affinity Resin for AAV8 and AAV9 Viral Vectors
Selectivity Ligand
Binding Capacity (vg/mL)
pH Stability
POROS™ CaptureSelect™
AAV9 High > 1014 pH range 1- 10
POROS™ CaptureSelect™
AAV8 High > 1013 pH range 1- 10
12-15kDa
AAV9
30
POROS™ CaptureSelect™ AAV8 and AAV9 – Performance Overview
Purity
Equivalent purity profile as conducting 3 steps of IEX Chromatography No residual proteins were detected Improved yield, ≥ 80% vector recovery
Process Yield
31
Process Optimization–Washing Away Cellular Debris
• Transfection reagents • Additives • Helper viruses
• Host Cell Proteins • Host Cell DNA • Plasmid DNA • Media
Components
AAV replicates in the nucleus of the cell and is not released until the cell undergoes apoptosis or is disrupted, additionally releasing:
32
Process Optimization – Secondary wash recommendations
Washing Agents: • 1M NaCl at various pH • MgCl2 • Chaotropic Salts • Arginine • Ethanol (phosphate buffers should be avoided) • Detergents • Glycol • Organics
33
POROS™ CaptureSelect™ AAV8 and AAV9 – Enabling Scale-Up
Low back pressure - <3.0 bar at 700 cm/H in 22 cm length column
Linear and predictable scalability
Manufacturing of AAV8 and AAV9 vectors feasible at large scale (confirmed up to 200L scale)
Affinity chromatography allows a simple, efficient and high yield process
Process Yield
34
• Affinity resins that offer high selectivity and capacity in the purification of viral vectors AAV8 and AAV9 for production of clinical grade gene therapy molecules
• A fast, robust, high yield and purity, from crude material in one step, purification process
• Significant improvement to the downstream processing, by reducing the purification steps and maximizing productivity
• Offer scalability and processing consistency
• Unique products designed specifically for AAV8 and AAV9 subtypes supported with Regulatory Support Packages.
POROS™ Affinity Resins - Gene Therapy Applications
Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only.
35
Polish Chromatography–Ion Exchange Solutions
pH 3
pH 9
pI
Anion exchange (AEX)
Cation exchange (CEX)
Full Empty Size 20 nM (200Å) 20 nM (200Å)
Density 1.40 g/cm3 1.32 g/cm3
average pI 5.9 6.3 Qu W, Wang M, Wu Y, Xu R. Scalable downstream strategies for purification of recombinant adeno-associated virus vectors in light of the properties. Curr Pharm Biotechnol. 2015;16(8):684-95.
36
Empty Capsid Removal Using POROS™ AEX Resins
• Empty capsids are a byproduct of vector biosynthesis
• Full vectors bound more tightly to the AEX resin
• All AEX POROS™ resins (XQ, HQ, D, and PI) have been shown to bind and elute the desired AAV capsid
• Superior resolution and capacity
0
200
400
600
800
1000
mAU
10.0 15.0 20.0 25.0 ml
Volume (ml)
Abs
orba
nce
280n
m (m
AU
)
____POROS HQ
____Q Sepharose FF
0
200
400
600
800
1000
mAU
10.0 15.0 20.0 ml
Volume (ml)
Abs
orba
nce
280n
m (m
AU
)
____POROS HQ
____Fractogel TMAE 650
37
Empty Capsid Removal Using POROS™ AEX Resins
• Slightly different anionic behavior was shown with empty capsids and full vectors using POROS™ AEX
• POROS™ HQ was optimized to efficiently separate empty capsids
G. Qu et al. / Journal of Virological Methods 140 (2007) 183–192
38
• Case Studies • Biosimilars & Recombinant Proteins • Virus Like Particles • Gene Therapy
• New products on the horizon
• Closing
Overview
39
POROS™ HIC Voice of Customer – Most important design features
Selectivity/Improved Resolution
Consistency of Performance
High Performance at Lower Salt
Concentration
Current focus of development
Incorporated in current prototypes
40
Prototype Design: Novel chemistries targeting best-in-class capacity and resolution
Increasing Hydrophobicity
41
High dynamic binding capacity
Stationary Phase Lysozyme DBC (C5) mg/mL
Leading commercially available ethyl 0.9
POROS HIC-1 7.0 Leading commercially
available low sub phenyl 13.5
POROS HIC-3 30.1 Leading commercially
available high sub phenyl 25.8
POROS HIC-5 37.2
Study Format: Column Dimensions: 0.66 cmD X 20 cmL Load Buffer: 1.5 M ammonium sulfate in 50 mM sodium phosphate (pH 7) Lysozyme Concentration: 1.5 mg/mL Flow rate: 300 cm/hr
42
Hydrophobicity effects resolution- A range is needed for varying applications
Inc
reas
ing
Hyd
roph
obic
ity
Study Format: Column Dimensions: 0.66 cmD X 20 cmL Load Buffer: 1.7 M ammonium sulfate in 50 mM sodium phosphate (pH 7) Buffer Gradient: Load buffer to 50 mM sodium phosphate (pH 7) in 10 CVs Flow Rate: 100 cm/hr Protein Mixture: Ribonuclease A, Lysozyme and Chymotrypsinogen & Chymotrypsin
Abso
rban
ce a
t 280
nm
(mAU
)
43
Aggregate Removal from a mAb
Load in PBS at pH 7.5 Column loaded at
100 mg mAb/mL of resin
44
Conclusion - Your Partner for Purification
• Performance-
• High specificity and capacity resins offering high purity in a single step
• Our solutions provide an industrialized purification platform for AAV production to support market needs
• Productivity - Our purification solutions improve process flow and reduce process time
• Capabilities- State-of-the-art manufacturing and robust quality
• Support- Technical engagement & global response
Enabling, purification solutions that simplify processes and reduce COGs
45
• Multi-function calculator, converter, and reference tool for process scientists
• https://www.thermoscientific.com/content/tfs/en/about-us/general-landing-page/mobile-apps.html
A New Tool for Chromatography Process Scientists…
Chromatography PRO
46
Chromatography PRO: Key Calculators
Column Calculator • Converts flow rates to linear
velocity from L/min, as well as calculating column sizes and cross sectional area.
Process Modeling • Models a given downstream
unit operation to understand column volumes, timing, throughput, etc.
Symmetry Calc • Calculates peak asymmetry,
number of theoretical plates, and HETP from volume, bed height, and peak calculations
Buffer Calculator • Calculates amount of buffer
required from molar solution and final volume
47
A solution that’s fits your needs
PHARMACEUTICAL GRADE REAGENT. FOR MANUFACTURING AND LABORATORY USE ONLY.
© 2016 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.
Perguntas?